Structure Therapeutics Inc.
GPCR Nasdaq
SEC CIK 1888886
Follow Structure Therapeutics
Weekly email: filings, results
Net income
−$144.8M
−120.3% vs same quarter last year
EPS, diluted
−$0.66
−78.4% vs same quarter last year
Operating cash flow
−$101.7M
−99.4% vs same quarter last year
Operating income
−$156.3M
−111.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$141.2M |
| FY24 | −$122.5M |
| FY23 | −$89.6M |
| FY22 | −$51.3M |
| FY21 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$225.8M |
| FY24 | −$117.9M |
| FY23 | −$81.7M |
| FY22 | −$46.3M |
| FY21 | - |